1. Articles from Michelson Diagnostics

    1-24 of 27 1 2 »
    1. Michelson Diagnostics: Imaging Reveals Changes in Blood Vessel Growth in Deadly Melanoma Skin Cance

      Michelson Diagnostics: Imaging Reveals Changes in Blood Vessel Growth in Deadly Melanoma Skin Cance

      A new clinical study has shown that Dynamic Optical Coherence Tomography imaging of melanomas (D-OCT) reveals changes to the blood vessels that correlate with the depth of invasion of the melanoma. Researchers believe this could lead to a new faster method of rapidly assessing how dangerous a given melanoma is. A more rapid assessment of the risk would potentially allow patients with more serious invasive disease access to the right treatment more directly, doing away with delays inherent in the traditional diagnosis. The technique may also lead to reducing the number of patients with less aggressive tumours receiving sentinel lymph ...

      Read Full Article
    2. New laser treatment could hold key to less-invasive skin cancer treatment

      New laser treatment could hold key to less-invasive skin cancer treatment

      Basal Cell Carcinoma is the most common form of skin cancer in the United States, with more than four million cases are diagnosed every year. Until now, surgery has been the standard treatment, but a new non-invasive option is helping cancer patients get rid of the disease. Will Leggett had basal cell carcinoma which his doctor was able to diagnose and treat using the new technique. Legett was scheduled for an invasive forehead flap surgery until he got a second opinion from Dr. Orit Markowitz at Mount Sinai Hospital in New York. “[Dr. Markowitz] said, ‘I think I can do ...

      Read Full Article
    3. VivoSight OCT used to visualize vascular networks in melanoma and non-melanoma skin cancers

      VivoSight OCT used to visualize vascular networks in melanoma and non-melanoma skin cancers

      Maidstone, UK, 3rd May 2016 New results have been published in Dermatology Online demonstrating that Michelson Diagnostics’ VivoSight OCT scanner can be used to image the blood vessel networks grown by skin cancers, and showing that skin lesions could be differentiated using their characteristic vascular patterns. This new technology may become a powerful tool in the dermatologists’s toolkit for the diagnosis of skin cancer and other conditions. The paper, entitled “Speckle-variance optical coherence tomography: a novel approach to skin cancer characterization using vascular patterns” was by Dr Orit Markowitz and co-workers from SUNY Downstate Medical Center, New Your Harbor ...

      Read Full Article
    4. Study shows VivoSight OCT is able to differentiate between actinic keratosis (AK) and basal cell carcinoma (BCC) by quantification of signal intensity and layer thickness

      Study shows VivoSight OCT is able to differentiate between actinic keratosis (AK) and basal cell carcinoma (BCC) by quantification of signal intensity and layer thickness

      Michelson Diagnostics, a medical device company focused on applications of multi-beam Optical Coherence Tomography (‘OCT’) technology, announces data confirming the ability for VivoSight OCT to differentiate between actinic keratosis (AK) and basal cell carcinoma (BCC). This statistically significant data proves VivoSight’s capabilities as a non-invasive, objective method for diagnosing and monitoring the treatment of these diseases. Data from this study, published in The Journal of the European Academy of Dermatology and Venereology (JEADV) , showed statistically significant differences in the signal intensities and the epidermal thickness measurements of AK and BCC. Results also showed an excellent correlation between OCT and ...

      Read Full Article
    5. Michelson Diagnostics: Use of VivoSight OCT Scanner Significantly Improves Early-Stage Diagnosis of Basal Cell Carcinoma and Reduces Need for Skin Biopsies

      Michelson Diagnostics: Use of VivoSight OCT Scanner Significantly Improves Early-Stage Diagnosis of Basal Cell Carcinoma and Reduces Need for Skin Biopsies

      Michelson Diagnostics, a medical device company focused on applications of multi-beam Optical Coherence Tomography (‘OCT’) technology, today announces data showing that use of its VivoSight OCT scanner significantly improves diagnosis of basal-cell carcinoma (BCC) at an earlier stage and reduces diagnostic biopsies by 36%. Scanning with VivoSight OCT provides clinicians with continuous images of the epidermis and superficial dermis of the skin that can be interpreted by a medical professional during the diagnostic process. The data, from a multi-centre, prospective study conducted in the US is published in the October issue of the Journal of Clinical and Aesthetic Dermatology . “The ...

      Read Full Article
    6. Michelson Diagnostics to present at Fortbildungswoche, Munich

      Michelson Diagnostics to present at Fortbildungswoche, Munich

      Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography (‘OCT’) technology, today announces that leading experts in the use of optical technology in dermatology will be presenting the benefits of multi-beam OCT at the 24th Annual Education Week for Practical Dermatology and Venereology, known as Fortbildungswoche, in Munich, Germany, 19-25 July 2014. The conference session on ‘Evidence for OCT diagnostics’ will take place at 12:15-13:15, Forum 9, on Friday 25th July. The presentations include: Optical coherence tomography scientific fundamentals and applications, Dr. Martina Ulrich Optical coherence tomography for basal cell carcinoma, Prof. Dr ...

      Read Full Article
    7. New study on non-invasive diagnosis of non-melanoma skin cancer with Melanoma Institute of Australia

      New study on non-invasive diagnosis of non-melanoma skin cancer with Melanoma Institute of Australia

      Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography (‘OCT’) technology, has commenced a clinical study to investigate the use of OCT to diagnose basal cell carcinoma in collaboration with the Melanoma Institute of Australia using Michelson’s Diagnostics VivoSight system. The study, run by Dr Pascale Guitera FACD PhD, will evaluate VivoSight’s ability to triage lesions which are superficial enough to be treated non-invasively and monitor the success, or otherwise, of non-invasive therapies. The study is designed to determine the potential to change clinical practice towards more non-invasive treatments of basal cell carcinoma ...

      Read Full Article
    8. Positive top line results from clinical trial for diagnosis of basal cell carcinoma using VivoSight OCT

      Positive top line results from clinical trial for diagnosis of basal cell carcinoma using VivoSight OCT

      Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography (‘OCT’) technology, announces positive top line results from the successfully completed multi-centre, prospective clinical trial for the diagnosis of basal cell carcinoma using VivoSight OCT. In the study, over 250 patients with clinically suspicious lesions for basal cell carcinoma were scanned at six centres in Germany. In each case, diagnosis using VivoSight OCT was compared with standard clinical diagnosis with and without dermoscopy. All results were verified by the gold standard of biopsy and histological analysis. Papers by Professor Dr. med. Julia Welzel, Dr. med. Martina ...

      Read Full Article
    9. Positive results from multi-centre, prospective clinical trial for diagnosis of basal cell carcinoma using Michelson Diagnostics’ VivoSight OCT Presented at AAD

      Positive results from multi-centre, prospective clinical trial for diagnosis of basal cell carcinoma using Michelson Diagnostics’ VivoSight OCT Presented at AAD

      Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography (‘OCT’) technology, today announces positive results from the successfully completed multi-centre, prospective clinical trial for the diagnosis of basal cell carcinoma using VivoSight OCT to be presented at the upcoming American Academy of Dermatology’s 72nd Annual Meeting (AAD) in Denver, Colorado, 21-25 March 2014. Papers by Professor Dr. med. Julia Welzel, Dr. med. Martina Ulrich discussing results from the clinical study will be presented in the AAD Conference Session F153 “Non-Invasive Imaging in Dermatology” on Tuesday, 25 March at 1.00pm. The presented results support ...

      Read Full Article
    10. Michelson Diagnostics announces completion of data collection in Vivosight OCT trial for BCC diagnosis

      Michelson Diagnostics announces completion of data  collection in Vivosight OCT trial for BCC diagnosis

      Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography (‘OCT’) technology, today announces that it has completed scanning and data collection for a large 250-patient, multi-centre, prospective clinical trial of the diagnostic performance of its VivoSight™ OCT scanner in diagnosing superficial basal cell carcinoma (BCC), the most common form of skin cancer. Preliminary results from the trial are to be announced at the American Academy of Dermatology (AAD) Annual meeting in Denver, in March 2014. It is expected that full results will be published in a leading peer-reviewed journal later in the year. The study ...

      Read Full Article
    11. Michelson Diagnostics to launch enhanced software for VivoSight OCT scanner

      Michelson Diagnostics to launch enhanced software for  VivoSight OCT scanner

      Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography (‘OCT’) technology, today announces the launch of its upgraded VivoSight OCT scanner with a new software technology that provides additional features for dermatologists to investigate skin lesions such as non-melanoma skin cancer. The VivoSight OCT scanner enables the dermatologist to see vertical cross-sectional images of sub-surface skin tissue to depths of 1-1.5 mm in high definition, providing the clinician with important information about the type, depth and lateral spread of the skin lesion that is not possible to determine from its surface visual appearance. Our ...

      Read Full Article
    12. Michelson Diagnostics targets malignant melanoma using OCT imaging with €2.3M EU funding

      Michelson Diagnostics targets malignant melanoma using OCT imaging with €2.3M EU funding

      Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography (‘OCT’) technology, announces that the European Union has awarded a €2.26 million Framework 7 grant to a consortium of seven partners, towards the cost of a project targeting malignant melanoma with OCT imaging. Using Michelson Diagnostics’ OCT imaging system, VivoSight, the project, named 'ADVANCE' (Automatic Detection of VAscular Networks for Cancer Evaluation), aims to demonstrate that multi-beam OCT imaging can be used to assess the aggressiveness of melanomas quickly and efficiently. Michelson Diagnostics is the lead partner in the ADVANCE project. Melanoma is the most ...

      Read Full Article
    13. Michelson Diagnostics Announces £1.98 Million Financing

      Michelson Diagnostics Announces £1.98 Million Financing

      Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, is delighted to announce the first closing of its Series A2 Financing. The round, which was oversubscribed, raised £1.98 million ( $3.25million ) from existing investors, led by Octopus Investments and supported by Catapult Venture Managers Ltd and London Business Angels, and several business angels. The funds will be used for several purposes including expanding VivoSight TM sales in Germany , where the system was launched in mid-2011 and where it is reimbursed for use in the diagnosis of non-melanoma skin cancer (NMSC), the commonest ...

      Read Full Article
    14. Michelson Diagnostics wins Regulatory Approval for VivoSight OCT Scanner in Australia

      Michelson Diagnostics wins Regulatory Approval for VivoSight OCT Scanner in Australia

      Michelson Diagnostics Press release: Michelson Diagnostics the UK based medical device company has been given regulatory approval by the Therapeutics Goods Administration (TGA) in Australia to start selling its market leading VivoSight OCT Scanner. Australia has the highest incidence of skin cancer in the world and the number of people needing treatment continues to grow. The Australian Institute of Health and Welfare and Cancer Australia estimates there were 430,000 new cases of Non-Melanoma Skin Cancer diagnosed in 2008. This is approximately four-fold higher than the number of new cases diagnosed in the UK. In a recent position statement, the ...

      Read Full Article
    15. Study shows VivoSight OCT could help Eyelid Cancer Surgery

      Study shows VivoSight OCT could help Eyelid Cancer Surgery

      Michelson Diagnostics Press Release - In what is believed to be the first ever study to investigate OCT (Optical Coherence Tomography) imaging of skin cancers in the eyelids and skin surrounding the eye, the Dept of Opthalmology, Maidstone and Tunbridge Wells NHS Trust have shown that OCT scanning can accurately reveal the margins of tumours. The study, which was conducted using the market leading VivoSight OCT scanner manufactured by Michelson Diagnostics, showed a positive correlation between tumour margins located using OCT and histology, the 'gold standard'. This breakthrough could ultimately lead to routine use of OCT scanning to plan delicate eyelid ...

      Read Full Article
    16. Optical Coherence Tomography: The first Quantitative Imaging Biomarker for Scleroderma

      Optical Coherence Tomography: The first Quantitative Imaging Biomarker for Scleroderma

      Michelson Diagnostics Press Release - Using the VivoSight OCT scanner, manufactured in the UK by Michelson Diagnostics Ltd, scientists at the Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds have developed the first quantitative imaging biomarker for skin involvement in Scleroderma. Scleroderma or Systemic Sclerosis (SSc) is a serious type of autoimmune disorder affecting approximately 1 in 10,000 people. It is a progressive disease that involves skin and internal organs by determining fibrosis, vasculopathy and immune system activation. The extent and severity of skin fibrosis is an important prognostic indicator of Scleroderma and often a primary endpoint in clinical ...

      Read Full Article
    17. Studies indicate that VivoSight OCT reliably predicts tumour margins

      Studies indicate that VivoSight OCT reliably predicts tumour margins

      Michelson Diagnostics Press Release - Accurate determination of tumour margins is vital to the successful treatment of skin cancer patients. This is especially the case for patients undergoing Mohs Micrographic Surgery where complete tumour removal may require repeated invasive procedures. Recent studies conducted in two US Healthcare facilities used the VivoSight OCT scanner, manufactured in the UK by Michelson Diagnostics Ltd, to prospectively refine clinically estimated tumour margins prior to Mohs Micrographic Surgery. The first 52 patient study 1 conducted by Professor Dan Seigel (Department of Dermatology, State University of New York Downstate Medical Center, Brooklyn, New York) concluded that: “OCT ...

      Read Full Article
    18. International imaging meeting highlights growing importance of OCT in skin cancer treatment

      International imaging meeting highlights growing importance of OCT in skin cancer treatment

      Michelson Diagnostics Press Release - Skin cancer is a big problem that is getting worse. Decades of insufficient sun protection are now catching up with an ageing population. While obvious non-melanoma skin cancers (NMSC) can sometimes be dealt with using surgery, widespread field cancerisation where a patient has multiple lesions on say the scalp or face is far more challenging. A holistic approach to assessing and treating the area of field cancerisation is urgently required to cope with the coming “avalanche” of patients. Optical Coherence Tomography (OCT) was highlighted as an increasingly important technology to help Dermatologists diagnose and monitor the ...

      Read Full Article
    19. Michelson Diagnostics participates in EU Funded project to develop new lasers for earlier, better diagnosis of major diseases

      Michelson Diagnostics participates in EU Funded project to develop new lasers for earlier, better diagnosis of major diseases

      Michelson Diagnostics Press Release - Michelson Diagnostics, manufacturer of the market leading VivoSight® OCT scanner, has been given a major role in an EU funded biophotonics consortium to develop a new generation of advanced lasers and light sources that are expected to deliver dramatic advances to diagnosis and treatment of skin cancer. The four year “FAMOS” project has 17 partners from 8 countries and is led by Professor Wolfgang Drexler at the Medical University of Vienna. The consortium will focus its efforts on un-met clinical needs where optical diagnosis could bring huge benefits such as: Replacing surgery with non-invasive treatments as ...

      Read Full Article
    20. Ex-Head of Galderma Xavier Yon joins Board of Michelson Diagnostics

      Ex-Head of Galderma Xavier Yon joins Board of Michelson Diagnostics

      Michelson Diagnostics Press Release - Ex-Galderma CEO Xavier Yon has joined the board of UK-based skin cancer scanner firm Michelson Diagnostics Ltd as non-executive Director. Xavier has spent more than 40 years in the medical industry, of which 15 years was spent as CEO of the major dermatology company Galderma. Under his leadership Galderma grew worldwide sales to $800 million; today Galderma employs more than 4,000 people in over 30 countries and has a turnover in excess of $1.4BN. Prior to joining Galderma Xavier’s career included senior positions with Pfizer, Solvay and Alcon. He holds board positions with ...

      Read Full Article
    21. Research Shows OCT Images Useful for Assessing Skin Cancer Thickness

      Research Shows OCT Images Useful for Assessing Skin Cancer Thickness

      Michelson Diagnostics Press Release - Research conducted at Guy’s and St Thomas’ NHS Foundation Trust in London has shown that a new skin imaging technology (Optical Coherence Tomography, or ‘OCT’), could be used for assessing the depth, and therefore the degree of malignancy, of the most common type of skin cancer. The work could enable greater and more effective use of non-invasive treatments for skin cancer, as an alternative to surgery, which can leave unsightly scars. The publicly funded research, published in the peer-reviewed journal Skin Research And Technology 1 (Wiley), was performed in a collaboration between the Medical Physics ...

      Read Full Article
    22. OCT in Dermatology Training Centre to be set up in Bonn Germany

      OCT in Dermatology Training Centre to be set up in Bonn Germany

      Michelson Diagnostics Press Release - Medinizinsches Zentrum Bonn Friedensplatz, the leading private medical centre in Bonn, Germany, will provide the world’s first training workshop for clinicians on the use and applications of Optical Coherence Tomography (OCT) in dermatology. Starting in the summer of 2012, the 1-day workshop will train clinicians on how to interpret OCT images of skin and to use the information to aid and improve their care of patients’ skin conditions, especially for non-melanoma skin cancer. Professor Uwe Reinhold, President of the Onkoderm network of top German skin cancer clinics and lead dermatologist at the Medinzinsches Zentrum Bonn ...

      Read Full Article
    23. Window on the skin reveals cancers

      Window on the skin reveals cancers

      Michelson Diagnostics Press Release - A revolutionary new scanner has been developed that will improve dramatically the accuracy of treatment for skin cancer, cutting NHS costs and reducing recurrence rates. The need: Non-melanoma skin cancer is becoming increasingly common. More than 100,000 cases are now diagnosed in the UK each year, according to Cancer Research UK. There are several different types of non- melanoma skin cancer and these are different from the types that develop from abnormal moles (melanoma). The standard cure is surgical removal, but until now, surgeons have had to guess how much skin tissue to remove around ...

      Read Full Article
    24. New Technique For Assessment of Scleroderma Using Vivosight OCT Wins The Abbot Innovation Award At British Society For Rheumatology

      New Technique For Assessment of Scleroderma Using Vivosight OCT Wins The Abbot Innovation Award At British Society For Rheumatology

      A presentation entitled “ Optical coherence tomography validation: a new quantitative imaging biomarker for affected skin in scleroderma ” by Dr Giuseppina Abignano at the Leeds Musculoskeletal Biomedical Research Unit has been awarded the Abbott Innovations Award at the British Society for Rheumatology’s annual conference earlier this month (image below). The research, undertaken at the Leeds Musculoskeletal Biomedical Research Unit, investigates the use of the VivoSight Topical OCT Probe, an innovative skin imaging technology, to assess tell-tale patterns in collagen deposits and vascularisation within the top layers of the skin of scleroderma sufferers. Scleroderma is a chronic multisystem autoimmune disease which ...

      Read Full Article
    1-24 of 27 1 2 »
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. Topics in the News

    1. (27 articles) Michelson Diagnostics
    2. (22 articles) Michelson Diagnostics Vivosight
    3. (13 articles) Jon Holmes
    4. (9 articles) Julia Welzel
    5. (7 articles) FDA
    6. (4 articles) Orit Markowitz
    7. (3 articles) Gordon Mckenzie
    8. (2 articles) University of Leeds
    9. (2 articles) Uwe Reinhold
    10. (2 articles) Mette Mogensen
  3. Popular Articles

  4. Picture Gallery

    Revolutionary Device For Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy Michelson Diagnostics announces £1.912M investment to drive sales growth of revolutionary skin cancer scanner Professor Julia Welzel hosts 1st International Optical Coherence Tomography User Meeting New Technique For Assessment of Scleroderma Using Vivosight OCT Wins The Abbot Innovation Award At British Society For Rheumatology OCT in Dermatology Training Centre to be set up in Bonn Germany Research Shows OCT Images Useful for Assessing Skin Cancer Thickness Ex-Head of Galderma Xavier Yon joins Board of Michelson Diagnostics Michelson Diagnostics: Use of VivoSight OCT Scanner Significantly Improves Early-Stage Diagnosis of Basal Cell Carcinoma and Reduces Need for Skin Biopsies Study shows VivoSight OCT is able to differentiate between actinic keratosis (AK) and basal cell carcinoma (BCC) by quantification of signal intensity and layer thickness VivoSight OCT used to visualize vascular networks in melanoma and non-melanoma skin cancers New OCT-A device allows imaging of nonsedated infants Are nuclei in stratified squamous epithelium high scattering or low scattering?